ROCHE HOLDING AG SIX:RO:
[AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR] ROCHE’S DIVARASIB SHOWS SUPERIORITY IN HEAD-TO-HEAD PHASE III TRIAL AGAINST APPROVED KRAS G12C INHIBITORS IN NON-SMALL CELL LUNG CANCER
ROCHE HOLDING AG - DIVARASIB ACHIEVES STATISTICALLY SIGNIFICANT IMPROVEMENTS IN PFS AND OS IN PHASE III STUDY
ROCHE HOLDING AG - DATA TO BE SUBMITTED TO HEALTH AUTHORITIES AND PRESENTED AT UPCOMING MEDICAL MEETING